Overview

A Study to Evaluate the Safety and Efficacy of RQC for AMD

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).
Phase:
Phase 2
Details
Lead Sponsor:
Paul A Knepper, MD PhD
Treatments:
Curcumin
Quercetin
Resveratrol